Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Best Practices for Employers to Maximize Uptake of Biosimilars
Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial cost savings while maintaining high-quality patient care.
EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability
EP: 2.The Economic Impact of Biosimilars
Now Viewing
EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars
EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars
EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption
EP: 6.Positioning Biosimilars in Clinical Practice
EP: 7.Assessing Patient Confidence With Biosimilars
EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars
EP: 9.The Growing Market for Biosimilars
EP: 10.Biosimilar Pricing Strategies: Understanding High-WAC and Low-WAC Models
EP: 11.The Biosimilar Shift: How PBMs Are Reshaping Formularies
EP: 12.The Road to Biosimilar Adoption: Navigating Interchangeability
EP: 13.How the IRA is Reshaping Biosimilar Adoption
EP: 14.Cost Savings Potential Associated With the Use of Biosimilars
Video content above is prompted by the following:
- What are best practices for employers working with pharmacy benefit managers and health plans to ensure maximal uptake and cost savings of biosimilars?
- Please share how you were able to achieve this in practice.
Related Content
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Article
Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
